Medical Device Network on MSN
Rivermark pockets $20M in Series D for late-stage prostate device trial
The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results